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0022-2836/$ - see front matter © 2006 ECholine kinase, responsible for the phosphorylation of choline to
phosphocholine as the first step of the CDP-choline pathway for the
biosynthesis of phosphatidylcholine, has been recognized as a new target
for anticancer therapy. Crystal structures of human choline kinase in its apo,
ADP and phosphocholine-bound complexes, respectively, reveal the
molecular details of the substrate binding sites. ATP binds in a cavity
where residues from both the N and C-terminal lobes contribute to form a
cleft, while the choline-binding site constitutes a deep hydrophobic groove
in the C-terminal domain with a rim composed of negatively charged
residues. Upon binding of choline, the enzyme undergoes conformational
changes independently affecting the N-terminal domain and the ATP-
binding loop. From this structural analysis and comparison with other
kinases, and from mutagenesis data on the homologous Caenorhabditis
elegans choline kinase, a model of the ternary ADP·phosphocholine complex
was built that reveals the molecular basis for the phosphoryl transfer
activity of this enzyme.© 2006 Elsevier Ltd. All rights reserved.*Corresponding author Keywords: choline kinase; phosphoryl transfer; crystal structureIntroduction
Phosphatidylcholine (PtdCho) represents the
most abundant class of phospholipids in eukary-
otic cells. Together with other phospholipids, such
as phosphatidylethanolamine and neutral lipids, it
is the major structural component of the mem-
brane bilayer. In addition to constituting 40–60% of
the phospholipid content of eukaryotic cell mem-
branes,1 PtdCho has been recognized as an
important source of second messenger molecules.2
The biosynthesis of phosphatidylcholine is primar-
ily accomplished by the CDP-choline pathway, also
called the Kennedy pathway. The first step of the
pathway is the phosphorylation of choline to







lsevier Ltd. All rights reservenase (CK) (E.C. 2.7.1.32).3 The level of PChol, which
is both a precursor and a breakdown product of
PtdCho, needs to be tightly regulated to maintain
cell integrity. Therefore, any changes in CK activity
may alter the total content of this component and its
ratio to other metabolites that play critical roles in
membrane structure and cell signaling processes.
Notably, cell-biological and genetic studies have
highlighted the interplay between the pathways for
PtdCho metabolism and Golgi-dependent secretory
processes.4,5
Several discoveries have recently revealed the
importance of PtdCho to mammalian cell physiol-
ogy. Alterations of PtdCho metabolism are associ-
ated to different key cellular events, such as
oncogenic transformation and programmed cell
death.6,7 Increased CK enzymatic activity, and
consequently increased levels of PtdCho, has been
detected in ras transformed cells.8 Similarly, CK is
overexpressed in breast, lung, colon, and prostate
tumors,7,9 and increased levels of PChol have been
detected by nuclear magnetic resonance studies of
human tumoral tissues.10,11 More recently, convinc-
ing evidence for the oncogenic potential of choline
kinase has been reported.12 From these studies,
choline kinase is thought to behave as an oncogened.







Full length hCKα2 83.1 0.098 0.41
Δ49N-hCKα2 71.5 0.072 0.45
hCKα1 18.6 1.69 0.35
Choline kinase activity was assayed as described in Materials and
Methods. The data were analyzed according to Michaelis-Menten
equation using the Microcal Origin version 5.0 non-linear curve-
fitting program.
137Structure of Human Choline Kinaseby itself, and lays downstream of RhoA GTPase-
dependent signaling processes. Although activation
of CK by RhoA is not mediated by a direct protein–
protein interaction, strong evidence that choline
kinase may be a new relevant molecule in RhoA-
induced oncogenic transformation has recently been
provided.12
Observations showing a direct link between
PtdCho homeostasis and carcinogenesis strongly
suggest the potential use of choline kinase as a new
marker for malignancy and, accordingly, as a
potential target for anticancer therapy. In fact, CK
inhibitors showing efficient antitumoral activity
have already been generated,13–16 and are currently
under investigation both in vitro and in vivo. Most
significantly, these studies have demonstrated that
inhibition of CK activity is reflected in a decrease of
PChol and total choline levels, leading to pro-
nounced antiproliferative effects in various human
tumor-derived cell lines and in animal models.17,18
However, it must be kept in mind that presently
available CK inhibitors may also affect other
molecules involved in signal transduction pathways
and cell cycle regulation.
In mammals, choline kinase exists as at least three
isoforms, encoded by two separate genes named ck-
α and ck-β. While ck-β codes for a single protein
(CK-β), ck-α undergoes alternative splicing and is
thus responsible for the production of two CK
isoforms, CK-α1 and CK-α2. Each isoform is present
as either dimers (homo- or hetero-) or as tetramers in
solution.19 To gain insight into the structural and
functional features of this family of enzymes, and to
facilitate the structure-based design of specific
inhibitors of human CKs, we solved the crystal
structure of human choline kinase isoform α2
(hCKα2) in its apo form and in complex with the
reaction products ADP or phosphocholine. These
structures allow us to identify for the first time the
substrate binding sites of CK, to correlate active site
residues with results from previous mutational
studies, and reveal the conformational changes
that occur upon substrate binding. In addition, the
structural analysis allowed us to generate a model of
the ternary hCKα2·ADP·PChol complex that reveals
the molecular basis for the enzymatic activity of
choline kinase.Results and Discussion
Overall structure
The human choline kinase (hCK) isoform hCKα2
used in this study consists of 457 amino acid
residues with a molecular mass of ∼52 kDa. The
protein was overproduced as an N-terminal trunca-
tion mutant. Table 1 shows the kinetic parameters
for full length and Δ49N-hCKα2 under identical
assay conditions, with choline as substrate. The
results demonstrate that the truncated construct has
very similar Vmax and slightly lower Km for cholinecompared to wild-type protein, indicating that the
non-conserved region at the N terminus of hCKα2 is
not essential for catalysis.
The structure of the human Δ49-hCKα2·Apoen-
zyme (hCKApo) was solved by the molecular
replacement method using as search model
coordinates from choline kinase A-2 of Caenorhab-
ditis elegans (CKA-2, PDB id 1NW1),20 and refined
at 2.15 Å resolution (Figure 1). Crystals of the
complex forms were obtained by soaking native
crystals with 10 mM ADP or 20 mM PChol,
respectively. Starting from coordinates of the
refined hCKApo, product-bound structures were
solved by the molecular replacement method and
refined to 3.1 Å and 2.4 Å resolution for the CK-
ADP complex and the CK-PChol complex, respec-
tively. For the dimer that makes up the asym-
metric unit, electron density clearly shows the
presence of a molecule of ADP in one of the
monomers of the Δ49-hCKα2·ADP (designated
hCKADP) complex, and of one PChol molecule in
each monomer of the Δ49-hCKα2·PChol (desig-
nated hCKPChol) complex. The observation of ADP
bound to only one of the two monomers could be
due to several factors, such as the rather high Km
of ADP (Table 1) or the environment in the
crystal. The refined structures (Table 2) exhibit
good stereochemical parameters with no residues
in the disallowed regions of the Ramachandran
plot.
The structure of hCKα2 reveals the typical euka-
ryotic protein kinase fold.20 Choline kinases and
aminoglycoside phosphotransferases (APHs) have
been classified as the most representative members
of the so-called “atypical kinases” (AKs) family of
enzymes. These enzymes clearly share homology
with the eukaryotic protein kinases (ePKs) catalytic
core but do not conserve all of the usual kinase
motifs.21 Recently the apo structure of the nematode
C. elegans choline kinase (CKA-2), which exhibits
42% sequence identity with hCKα2, has been
reported.20 Comparison of the protein structures
reveals a similar folding topology between these
two choline kinases. While the mean deviation of
position between corresponding Cα atoms encom-
passing the complete structure is relatively large
(rmsd of 3.4 Å between the two apo forms), the
individual domains overlay with a smaller rmsd
(1.48 Å and 1.94 Å for the N and C-terminal
Figure 1. Ribbon diagram of apo hCKα2, and with ADP and PChol molecules concomitantly present as modeled on
the basis of the determined hCKADP and hCKPChol complex structures. (a) hCKApo dimer (gray/yellow ribbon) oriented
with the 2-fold non-crystallographic axes perpendicular to the plane of the page. Dimer formation buries 2100 Å2, where
helix 2 plays a major role. (b) Stereo diagram of a hCKα2 monomer drawn after a vertical rotation of 90° with respect to
the orientation in (a). Key structural elements are colored: the ATP-binding loop in blue, the dimer interface α-helix in
cyan, the short β-strand that links the N and C-terminal domains in yellow, the Brenner's motif in red, and the choline
kinase motif in green. In this and the following Figures, ball-and-stick representation of ADP and PChol molecules are
shown with their carbon atoms colored in orange and green, respectively. Oxygen, nitrogen and phosphate atoms are
shown in red, blue and magenta, respectively. All structure Figures were made with Pymol. [http://www.pymol.org].
138 Structure of Human Choline Kinasedomains, respectively). The most significant differ-
ence centers at residues 262–281 (hCKα2 number-
ing). This segment comprises an α-helix in hCKα2(Figure 1(a) and (b), helix 5) instead of two short β-
strands (7 and 8, CKA-2 numbering), and is not part
of any catalytically relevant region. Each monomer
Table 2. Data collection and refinement statistics
Apo ADP P-Chol
X-ray source CHESS-A1 APS-SerCAT-ID22
Resolution (Å) 2.15 3.1 2.4
Space group P212121 P212121 P212121
Cell (Å) 56.2, 122.8, 132.1 52.3, 127.1, 158.7 52.5, 128.3, 172.2
Rsym
a,b 11.0 (62.5) 14.7 (61.2) 11.4 (57.4)
Completeness (%)a 99.9 (100) 99.3 (93.9) 99.8 (99.1)
I/σ(I)a 20.38 (5.76) 16.2 (2.3) 13.9 (3.2)
Total reflectionsa 906,892 (113,984) 190,216 (12,100) 375,565 (31,936)
Unique reflectionsa 50,560 (6366) 19,759 (1806) 46,369 (5201)
Redundancya 17.9 (17.9) 9.6 (6.7) 8.1 (6.1)
R-factor (Rfree)
c 19.8 (25.6) 26.3 (32.8) 21.4 (25.8)
No. of non-hydrogen protein atoms 5686 4627 5576
No. of water molecules 417 26 109
No. of cofactors atoms – 27 22
rmsd bond length (Å)d 0.014 0.010 0.009
rmsd bond angle (°)d 1.371 1.369 1.225
Average B factor (Å2) 35.99 51.31 35.66
Ramachandran plote, %
Most allowed 93.2 83.4 92.9
Additional allowed 6.7 14.8 7.0
Generously allowed 0.2 1.8 0.2
Disallowed 0.0 0.0 0.0
a Data for the highest resolution shell are given in parenthesis.
b Rsym=∑h∑i|Ii(hkl)–<I(hkl)>|/∑h∑iI(hkl).c Rfactor=∑||Fobs|–|Fcalc||/∑|Fobs|Rfree is the Rfactor value for 5% of the reflections excluded from the refinement.d Root mean square deviations (rmsd) from ideal values calculated with Refmac.39
e Figures from Procheck.44
139Structure of Human Choline Kinaseof the asymmetric unit dimer is composed of two
domains connected by a short β-strand (residues
211–214) (Figure 1(a) and (b), strand F). Note that in
this, and other Figures presented here, we modeled
the presence of both substrates, so as to better orient
the two binding sites. However, our structures of
hCKα2 contain either no substrate, only PChol, or
only ADP.
The N-terminal 30 amino acid residues (residues
49–80) of our construct are not visible in the electron
density maps of all three structures, indicating that
they are disordered in the crystals. The smaller
domain of the two-domain enzyme, the N-terminal
domain, is composed of a five-stranded antiparallel
β-sheet and a single α-helix (Figure 1(a) and (b),
helix 1 and β-strands A–E). Inserted between the
third (C) and the fourth (D) strands of this β-sheet is
an α-helix that forms the interface stabilizing the
protein as a dimer (Figure 1(a) and (b), helix 2).
Amino acids belonging to the region connecting the
third β-strand with the interface helix are not visible
in electron density maps of all three structures
(residues 152–176, Figure 1(b), black-broken line).
Interestingly, this sequence segment represents the
only difference between human choline kinase α1
and α2, in which an additional 18 amino acid
residue insertion is incorporated in α2. Although
further studies are required to completely elucidate
the function of this 18 amino acid residue insertion,
we observed that when present (i.e. in hCKα2) the
insertion lowers the Km for choline to 0.10 mM, in
comparison to the much higher value of 1.69 mM for
hCKα1. How this dramatic lowering of choline Km is
achieved cannot be conclusively answered by ourstructures. However, a structural analysis of this
region reveals that it may be important for facilitat-
ing the conformational changes that take place upon
substrate binding.
The C-terminal domain is primarily helical, and
contains many of the conserved and functionally
important residues. The loop comprising residues
302–311 (Figure 1(b), red) is the so-called Brenner's
motif,22 whereas the region including residues 326–
349 (Figure 1(b), green) is the choline kinase motif.
Several residues belonging to these motifs are highly
conserved among CKs, ePKs and APHs, and have
critical catalytic functions (Figure 2).
ATP binding site
The structure of the hCKADP complex reveals how
the nucleotide is bound in a cleft between the two
domains of the enzyme. Residues from both the N
and C-terminal lobes contribute to the formation of a
large pocket in which the nucleotide (ADP or ATP)
binds (Figure 1(b)).
The adenine ring makes H-bond interactions
between the N1 and N6 atoms and the polypeptide
backbone carbonyl oxygen of Ile209 and Gln207
(Figure 3(a) and (b)). The N6 atom is also within
H-bond distance from the side-chain OE2 of Glu206.
These interactions explain the specificity of hCKα2
for ATP, and are consistent with the observation that
no enzymatic activity was detected when non-ade-
nine containing NTPs were substituted for ATP in the
enzyme assay (data not shown). In addition, two
conserved hydrophobic residues (Leu144 and
Leu313) are positioned on both sides of the adenine
Figure 2. Sequence alignment of choline kinases, APH(3′)-IIIa and cAPK obtained with the ClustalW algorithm. Key
structural elements are shaded with different colors according to Figure 1(b). Residue that directly interact with ATP are
marked by an a, those with choline by a c, and the hydrophobic residues that surround the choline by an h. Residues
revealed by mutagenesis experiments to play a structural role are labeled with an s. hCK denotes human choline kinases,
mCK from mouse, and cCK from C. elegans. The sequence alignment for APH(3′)-IIIa (APH) and cAPK is shown only for
catalytically important residues. Sequence breaks for the latter two are denoted with // and sequence not included in this
alignment with period marks (..). Gaps in a sequence are marked with - -. The region marked with black broken line
represents the 18 amino acid residue insertion that distinguishes hCKα-2 from hCKα-1 and that is not visible in all our
crystal structures. The first residue in ourΔ49-hCKα-2 construct is indicated by an arrow, and so is the first visible residue
in our crystal structures.
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141Structure of Human Choline Kinasering, contributing therefore to the right positioning
and binding of the nucleotide. The ribose component
interacts with the protein via H-bonds between the
polypeptide backbone carbonyl oxygen of Ser211 and
the O2′ of the sugar, and between the backbone
amide of Arg213 (modeled as alanine) and the O3′ of
the sugar. Correct positioning of the ribose is also
assured by the conserved Leu124 (see Table 3 for a list
of ADP–enzyme interactions).
The interactions of the nucleotide phosphate
groups involve the side-chains of conserved active
site residues. The α-phosphate makes polar inter-
actions with the side-chain NH1 atom of Arg146,
positioned on the N-terminal five-stranded anti-
parallel β-sheet of hCKα2 and conserved among all
CKs and ePKs. Its side-chain projects toward the
ATP binding pocket, and its position is consistent
with the invariant lysine in ePKs that directly
participates in nucleotide binding.23 The α-phos-
phate also makes H-bond interactions with
Asp330, a catalytically critical residue residing in
the choline kinase motif. This residue is conserved
among all CKs, ePKs and APHs, and when
mutated it completely abolishes CK activity.24 In
APH(3′)-IIIa this Asp is essential for the coordina-
tion of two Mg2+ that bind to ATP. The electron
density map of our hCKADP crystal structure does
not show any peak interpretable as metal ion in the
active site.
The β-phosphate forms H-bond interactions with
two protein atoms. Both O1B and O2B atoms
interact with the atom ND2 of Asn122: this residue
is also highly conserved among CKs and ePKs. In
addition, the O3B atom of the β-phosphate forms H-
bond interactions with both NE and NH2 of Arg117.
This last residue shows different conformations
between the three crystal structures: in hCKApo,
Arg117 points towards the empty active site,
positioned where we observe the ADP molecule in
hCKADP; in hCKADP the Arg117 side-chain moves
out so to accommodate the ADP molecule and make
interactions with its β-phosphate; in hCKPChol
Arg117 points in the opposite direction to the active
site, towards the solvent accessible exterior of the
protein, making no interactions with neighboring
residues. Both Arg117 and Asn122 belong to the
loop connecting the first and second strands of the
N-terminal β-sheet, earlier defined as the ATP
binding loop20 (residues 116–124). This loop is the
equivalent of the P loop in protein kinases,25 and
from comparison of the apo and PChol-bound
crystal structures, we observe its shift from an
open to a closed conformation upon choline-binding
(see below).
Choline-binding site
Choline is the best substrate for hCKα2 with a Km
of 0.07 mM and a kcat of 71.5 s
−1 (Table 1). We first
performed extensive co-crystallization and soaking
experiments with choline. However, both soaked
crystals and those obtained by co-crystallization did
not contain a bound substrate molecule as inferredfrom the inspection of electron density maps. We
next performed soaking experiments with PChol
and were able to solve the crystal structure of the
complex hCKPChol.
The electron density map of hCKPChol, calculated
at 2.4 Å resolution, reveals a strong peak close to the
position of the β-phosphate of ADP as seen in
hCKADP (Figure 4(a)). Residues belonging to the
Brenner's motif (302–311) and the choline kinase
motif (326–349) on the C-terminal domain partici-
pate in the binding of the choline moiety. The
phosphate O3 atom of PChol is positioned within
H-bond distance from the side-chain atoms of
several conserved active site residues: NE2 of
Gln308, OD2 of Asp306, and ND2 of Asn311.
These residues belong to the Brenner's motif and
except for Gln308, that is conserved only among
CKs, are absolutely conserved among all ePKs and
APHs. Asp306 plays a critical role in catalysis, as
inferred from mutagenesis data and from previous
studies on the corresponding residues in ePKs and
APH(3′)-IIIa.26,27 The phosphate O2 atom of PChol
forms an H-bond with the backbone amide of
Leu120. This residue is conserved among all CKs
and belongs to the ATP binding loop, as well as
Ser121 that makes one H-bond interaction between
its OG atom and the phosphate O4 atom of PChol
(see Table 3 for a list of PChol–enzyme interactions).
An extensive network of polar interactions char-
acterizes the residues involved in the choline-
binding site (Figure 4(a) and (b)). Asp306 makes
H-bond interactions with two water molecules,
interacting with the neighboring Asp330 on one
side, and with Asn345 and Glu349 on the opposite
side. Both Asn345 and Glu349 are conserved among
all CKs, and participate in H-bond interactions with
residues at the base of the choline-binding site.
Mutagenesis of Glu349 to Ala results in loss of
enzyme stability, and this residue seems to have
both a catalytic and a structural role.24 Asp330
interacts via H-bond with the conserved His304
residue that has a structural role in the active site, as
suggested by its mutation to Ala that results in loss
of stability.24 Emanating from His304 is an addi-
tional network of H-bond interactions that involve
two other conserved and important residues:
His236, present in all CKs, ePKs and APHs, and
Asp342, found in all CKs and APHs. Mutation to
Ala of this last Asp residue has recently been shown
to be responsible for activity inhibition and disrup-
tion of the homo-dimer complex in mouse CK-α1.28
The architecture of the choline-binding site can
be described as a deep hydrophobic groove with a
rim composed of negatively charged residues
(Figure 5). Thus, both hydrophobic and electrostat-
ic forces are responsible for the interaction between
hCKα2 and choline.29 The conserved patch of
negatively charged residues (Glu215, 217, 218,
309, 349, 357, 434, and Asp353) at the outer
boundary of the choline-binding site (Figure 5(b))
can function to direct the choline molecule into the
active site. This phenomenon of electrostatic steer-
ing has been described previously as a mechanism
Figure 3 (legend on opposite page)
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Table 3. Enzyme–products interactions
Protein residues and atoms ADP Distances (Å)
Polar interactions
Arg117 NH2a O3B 2.78
Arg117 NE O3B 3.32
Asn122 ND2 O4B 3.32
Asn122 ND2 O2B 3.46
Arg146 NH1 O1A 2.67
Glu206 OE2 N6 3.48
Gln207 O N6 2.63
Ile209 O N1 3.44
Ser211 O O2′ 2.70
Arg(Ala)213 Nb O3′ 3.15
Asp330 OD2 O1A 3.25
Asp330 OD2 O2A 2.91
Hydrophobic interactions
Leu124 Ribose ∼3.5
Leu144 Adenine base ∼4
Leu313 Adenine base ∼4
Protein residues and atoms PChol Distances (Å)
Polar interactions
Leu120 N O2 2.84
Ser121 OG O4 2.69
Asp306 OD2 O3 2.28
Gln308 NE2 O3 3.01







a Atomic numbering for the products is shown accordingly
with Ligplot drawings for ADP (Figure 3(b)) and PChol (Figure
4(b)).
b Arg213 was modeled as an alanine due to lacking side-chain
electron density.
143Structure of Human Choline Kinaseto influence the catalytic rate.30 While the outer
surface of the choline-binding site is dense with
negatively charged residues, the base of the pocket
that defines the direct choline-binding site is
constructed of conserved aromatic residues
(Tyr333, 354, 440, and Trp420, 423; see Figure 5
(c)). Once choline is positioned in the active site, its
positively charged quaternary amine is stabilized
by interactions with the rings of the aromatic
residues. Mutagenesis data show that among the
hydrophobic conserved residues Trp420 plays a
critical role in rate enhancement. In addition,
guanidinium hydrochloride-induced denaturation
data suggest its involvement in maintaining the
overall stability of the enzyme.24Figure 3. The ATP binding site. (a) Stereo view represent
omit map (red) and sigma-a weighted 2Fo–Fc map (blue) bo
position of PChol is shown for orientation purposes. The pr
shown in grey, red, blue and magenta, respectively. H-bond
showing the interactions of ADP with hCKα2. Broken lines in
hydrophobic contacts between carbon atoms of the nucleoti
oxygen, nitrogen and phosphorous atoms are colored orange
could not observe side-chain density for Arg213 so this residuConformational changes and catalysis
To delineate the conformational changes occurring
during catalysis, we compared the two product-
bound structures with hCKApo. Both complexes
where superposed on hCKApo using the C
α atoms of
residues 90–209 (N-terminal domain), and the Cα
atoms of residues 212–457 (C-terminal domain)
independently (Figure 6). We could not detect
significant conformational changes between hCKApo
and hCKADP. This could partly be due to the relatively
low resolution of the hCKADP structure (3.1 Å). In
contrast, PChol binding gives rise to a significant
conformational change that manifests itself both
globally, as change in the relative orientation of the
N-terminal domain (Figure 6(a)), and locally, as
change in the position of the ATP binding loop
(Figure 6(b)).
Superposition of hCKADP and hCKPChol on the
hCKApo reveals that upon PChol binding the N-
terminal domain of hCKPChol rotates relative to the
C-terminal domain by about 16 degrees. This
movement is corroborated by analyzing all three
structures using the automated methods implemen-
ted in DynDom.31 The domain rotation results in a
movement of the ATP binding loop by about 10 Å
(Figure 6(a)). Pivot points between the two domains
can be localized in the zone of the interface,
specifically around three segments that include
amino acid residues 176–179, 195–196 and 211–214.
The last two segments form a double hinge just at
the linker between the two domains, while the
segment 176–179 is positioned at the end of the 18
amino acid residues insertion that distinguishes
hCKα2 from hCKα1. As pointed out before, this
segment is not visible in the electron density maps of
all three structures. Together with the observation
that its presence influences the catalytic activity of
hCKα2 (Table 1), this segment most likely plays a
critical role in the protein domains rearrangements
and the associated catalytic function.
Superposition only of the individual N-terminal
domains of the three structures reveals that the ATP
binding loop is subjected to a local conformational
change independently from the above-mentioned
domain rotation. Upon PChol binding, the loop
undergoes a shift covering about 7 Å, from an open
conformation (as observed in hCKApo and hCKADP)
to a closed conformation (Figure 6(b)). In contrast,
superposition of the C-terminal domains of all three
structures reveals that it is not involved in any
significant conformational movement upon ligand
binding (Figure 6(c)).ation of the ATP-binding site. 2Fo–Fc simulated annealing
th contoured at 1 σ are shown around ADP. The relative
otein carbon, oxygen, nitrogen and phosphate atoms are
s are shown as cyan broken lines. (b) Ligplot45 drawing
dicate all potential H-bonds. “Radiating” spheres indicate
de and the neighboring residues. Ligand-bonds, carbon,
, black, red, blue and purple, respectively. Note that we
e was modeled as an alanine.
Figure 4 (legend on opposite page)
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Figure 5. Choline-binding site architecture. (a) Surface representation of hCKPChol (same orientation as in Figure 1(b))
colored on the basis of the electrostatic potential of the molecule (ranging from −15, red, to +15 kT/e, blue) calculated by
APBS,46 as implemented in Pymol. (b) Zoom of the choline-binding groove, where hydrophobic and negative residues are
shown as yellow and red surface, respectively. (c) Stereo view of the interactions between the quaternary ammonium
moiety of choline and hydrophobic conserved residues (yellow sticks). Solvent-accessible negatively charged residues are
shown in gray sticks. Oxygen, nitrogen and phosphorous atoms are red, blue and magenta, respectively.
145Structure of Human Choline KinaseFunctional residues
The reaction catalyzed by choline kinase is the
phosphorylation of choline by ATP in the presence of
Mg2+, yielding phosphocholine and ADP. The clari-
fication of the mechanism of phosphoryl transfer
would represent an important advancement for
developing better inhibitors of choline kinase. The
presence of five structurally and functionally con-
served residues among CKs, APHs and ePKs (Ser121,
Arg146, Asp306, Asn311 and Asp330), together with
the recently publishedmutagenesis studies on cholineFigure 4. Choline-binding site interactions. (a) Stereo
simulated annealing omit map (red) and sigma-a weighted
surrounding PChol. Coloring scheme as in Figure 3, plus water
showing the interactions of PChol with hCKα2. Ligand-bonds a
colors are as in Figure 3(a). Water molecules are shown as cyakinase from C. elegans,24 permit us to introduce with
reasonable precision a model of the ternary enzy-
me·ADP·PChol complex (Figure 7(a) and (b)). In
addition, our model includes two magnesium ions:
one that bridges the α and β-phosphates of ADP, and
a second that bridges theβ-phosphate of ADP and the
phosphate of PChol. Support for a model containing
two magnesium ions comes from comparison of our
structures with the homologous structures of APH
(3′)-IIIa (PDB id 1J7U)23 and cAPK (PDB id 1ATP),26
where two metals are observed, and from the
presence of essential residues in hCKα2 that areview representation of the choline-binding site. 2Fo–Fc
2Fo–Fc map (blue) both contoured at 1 σ are shown
molecules depicted as cyan spheres. (b) Ligplot45 drawing
re colored green. Broken lines, radiating spheres and atom
n spheres.
Figure 6. Conformational change in hCKα2 upon substrate binding. Overlay of the two product-complex structures
on hCKApo. hCKApo, hCKADP and hCKPChol are shown as yellow, red and green C
α-trace, respectively. (a) Stereo view
showing the overlay of the complete monomers from the three structures. The superposition matrix was calculated using
residues only from the C-terminal domain (as in (c)). The green arrow shows the movement of the N-terminal with respect
to the C-terminal domain. (b) Overlay of the N-terminal domain. The rmsd values between hCKApo and hCKADP are
0.44 Å for 84 atoms, and between the hCKApo and hCKPChol are 0.77 Å for 94 atoms. (c) Overlay of the C-terminal domains.
The rmsd values between hCKApo and hCKADP are 0.5 Å for 228 atoms, and 0.27 Å between hCKApo and hCKPChol for 244
atoms.
146 Structure of Human Choline Kinaseoptimally placed for the ligation of these magnesium
ions in the hCKα2 active site.
In the modeled active site, Ser121 supplies one of
the six ligands to the magnesium ion that bridges
the two substrates. In P-loop containing proteins, a
serine or threonine residue participates directly in
magnesium coordination. It seems that in hCKα2
the participation of such a serine residue is
maintained despite the lack of a P-loop. This
important role for this amino acid is consistent
with mutagenesis data. Mutation of Ser121 to Ala in
CKA-2 results in a pronounced decrease in catalytic
efficiency for both ATP (9% of wild-type) and
choline (2.7% of wild-type).24 However, the Ser to
Thr mutant has almost the same efficiency as wild-type, supporting the importance of an-OH group at
this position for full activity. An alternative role for
this residue would be to position the phosphocho-
line. In such a case, an additional water molecule is
required to complete the octahedral magnesium
coordination.
In addition to the above serine residue, our model
calls for the aspartic acid residues at positions 306
and 330 to participate in coordinating the magne-
sium ion bridging the ADP and PChol molecules.
Several studies demonstrate the critical importance
of Asp306 in catalysis. When this Asp is mutated to
Ala or Asn, CKA-2 shows total loss of activity, while
when changed to Glu it retains 0.1% of the wild-type
rate.24 Our structural analysis suggests that Asp306
Figure 7. Model of the ternary ADP-PChol complex. (a) Scheme showing H-bond interactions between hCKα2
residues and ADP or phosphocholine, as well as coordination of twoMg2+, as black broken lines. (b) Stereo representation
of the modeled ADP–PChol complex. This model was generated based on the closed hCKPChol structure, and analogy to
APH(3′)-IIIa and cAPK. See the text for details.
147Structure of Human Choline Kinaseplays the essential role of positioning a water
molecule that ligates to a magnesium ion. Such an
interpretation is consistent with structural data on
APH(3′)-IIIa and cAPK where the corresponding
residues, Asp190 and Asp166, respectively, were
observed to be within H-bonding distance to a water
molecule involved in magnesium ligation. While
Asp306 interacts with the magnesium ion via a
water molecule, Asp330 does so directly. Mutation
to Ala, Asn or Glu of this residue results in lack of
any detectable enzymatic activity in CKA-2,24
supporting a critical role for this residue. In fact, in
our model Asp330 directly interacts with both
magnesium atoms. A similar role was observed for
the homologs aspartic acid in APH(3′)-IIIa (Asp208)
and cAPK (Asp184).
In addition to the magnesium atom bridging the
products, our modeling studies suggest the presenceof a second magnesium ion that coordinates Asn311
and ADP. Mutagenesis of Asn311 to Ala in CKA-2
shows a severely impaired enzyme, with a kcat only
0.3% of wild-type, a 36-fold increase in apparent Km
for Mg2+, and a slight increase in Km for ATP. In our
model Asn311 interacts via its side-chain oxygen
with the metal ion. The corresponding magnesium-
ligating residue in APH(3′)-IIIa is Asn195, and in
cAPK it is Asn171.
Asparagine 122 and glutamine 308 are residues
conserved just in the CK family, and this could
suggest a distinctive function with respect to APHs
and ePKs. In our model the side-chain of Asn122
maintains its interaction, as seen in the hCKADP
structure, with the β-phosphate of ADP. Similarly,
Gln308 preserves its interaction with the phosphate
group of PChol. Thus, these residues act to correctly
position the substrates for phosphoryl transfer.
148 Structure of Human Choline KinaseIn analogy with the invariant Lys residues of APH
(3′)-IIIa (Lys44) and cAPK (Lys72) which directly
participate in nucleotide binding,24 Arg146 (in
hCKα2) projects toward the ATP binding site and
makes interaction with the nucleotide α-oxygen
atom. Mutation of this Arg residue to Ala has a
significant effect on the Km for ATP, but not on the
kcat,
24 consistent with mutagenesis data on Lys44 of
APH(3′)-IIIa.23 These observations suggest an anal-
ogous important contribution of Arg146 in substrate
binding and positioning.
In summary, here we report the crystal structures
of human choline kinase α2 in the apo form and in
complex with the products ADP or phosphocholine.
While no significant conformational changes are
observed upon ADP binding, PChol induces a
significant rotation of the N-terminal domain rela-
tive to the C-terminal domain, in addition to
triggering a closing of the ATP binding loop.
Modeling the simultaneous presence of ADP and
phosphocholine in the closed conformation of the
enzyme exposes the active site residues involved in
substrate recognition, magnesium ions coordination,
and catalysis. Unfortunately, despite extensive
efforts we were unable to obtain crystals of hCKα2
in the presence of the inhibitor hemicholinium. It
would be interesting to determine which conforma-
tion of the enzyme is recognized by the current
choline kinase inhibitors that are being tested as anti-
proliferative agents. Also, as these inhibitors contain
several aromatic rings and possess a positive charge
due to a quaternary nitrogen, it would be important
to ascertain if the binding of these inhibitors exploit
the choline-binding site, which is composed of
several conserved hydrophobic residues. A deeper
understanding of both the structure and themechan-
isms regulating the activity of human CK at the
molecular level will pave the way to the identifica-
tion of novel compounds that selectively interfere
with this enzyme to suppress elevated levels of
choline-derived phospholipids in cancer cells.Materials and Methods
Materials
All chemicals were reagent or molecular biology grade.
Platinum Pfx polymerase was from Invitrogen. dNTPs
were from Promega. Restriction endonucleases and DNA
size markers were from New England Biolabs. Agarose
gel purification, PCR product clean-up and plasmid mini
prep columns were all products of Qiagen. Human liver
cDNA library was a product of ResGen (Invitrogen). All
oligonucleotides were supplied by IBA GmbH, Göttingen,
Germany. Choline and pyruvate kinase were from Sigma.
T4 DNA ligase, ATP, NADH, phosphoenolpyruvate and
lactate dehydrogenase were purchased from Roche.
DNA amplification by PCR
Standard PCR reaction mixture consisted of Pfx
amplification buffer, 0.3 mM of each dNTP, 1.5 mMMgSO4, 1.0 μM of each primer, DNA template (200 ng for
cDNA library and 10 ng for plasmid) and 1.25 unit of
Platinum Pfx DNA polymerase in a total volume of 50 μl.
Standard thermal cycling protocol was based on three-
step cycling procedures with initial denaturation of the
template for 10 min at 94 °C, followed by 30 cycles of
denaturation at 94 °C for 1 min, primer annealing at 50 °C
for 1 min and primer extension at 68 °C for another 2 min.
A final extension step at 68 °C for 5 min was introduced
after the cycling reactions.
Cloning of full length and Δ49N-hCKα2
Based on the sequence information of hCKα2 previous-
ly reported by Hosaka et al.,32 the cDNA sequence of
hCKα2 was PCR amplified from human liver cDNA
library in two overlapping fragments. The first fragment
was generated by using the sense primer 5′-GGGAATTC-
CATATGAAAACCAAATTCTGCACCG-3′ (CM14) and
antisense primer 5′-CTTGTTCAGAGCCCTCTTTATTAC-
3′ (CM17). The second fragment was amplified by sense
primer 5′-GTAATAAAGAGGGCTCTGAACAAG-3′
(CM16) and antisense primer 5′-CGCGGATCCTCA-
CACCCCAAGCTTCCTC-3′ (CM15). CM14 and CM15
carry NdeI and BamHI cloning sites, respectively. CM16
and CM17 are mutagenesis primers for deletion of the
internal BamHI site. Both fragments were subsequently
joined by PCR using primers CM14 and CM15. The
resulting PCR product with the size corresponding to the
full-length hCKα2 was treated with the restriction
enzymes NdeI and BamHI and ligated into the pGEX-
RB vector33 to create pGEX-RB-hCKα2.
Δ49N-hCKα2 was generated from pGEX-RB-hCKα2
using the sense primer 5′-GGGAATTCCATATGGGC-
CAACAGCCGCCGCTCGCGCTGC-3′ (WC62) and
CM15 as antisense primer. The resulting PCR product
was digested with NdeI and BamH1 and ligated into
pGEX-RB to give pGEX-RB-Δ49N-hCKα2. In all cases,
clone integrity was confirmed by sequencing. The
rationale behind this deletion construct was to generate
a construct that starts with the first residue observed in the
structure of choline kinase A-2 from C. elegans,20 and in
this way obtain a protein that is more amenable to
structural studies, but yet maintains its full catalytic
function.
Protein expression and purification
Recombinant glutathione-S-transferase (GST)-tagged
Δ49N-hCKα2 was produced in Escherichia coli strain
BL21(DE3) containing the vector pGEX-RB-Δ49N-
hCKα2. After induction with 1 mM IPTG for 18 h at
25 °C, the soluble fraction of the cell lysate was loaded
onto a glutathione-Sepharose column (Amersham). The
purification included proteolytic cleavage of the GST tag
with thrombin, anionic exchange chromatography via
ResourceQ, and size-exclusion via Superdex-200 column
(Amersham). The protein eluted at a volume consistent
with a dimeric molecule. The full-length protein was
purified using a similar protocol.
Enzyme assay
Choline kinase activity was assayed spectrophotomet-
rically using a modified pyruvate kinase/lactate dehy-
drogenase-coupled system.34 The reaction contained
100 mM Tris-HCl buffer (pH 7.5), 100 mM KCl, 10 mM
149Structure of Human Choline KinaseMgCl2, 0.5 mM phosphoenolpyruvate, 0.25 mM NADH,
four units of pyruvate kinase, five units of lactate
dehydrogenase, purified enzyme, and substrates in a
total volume of 1 ml. For determination of steady-state
kinetic parameters the concentration of one substrate was
kept constant at 2 mM ATP or 4 mM choline while the
concentration of the other was varied. The reaction
performed at 37 °C was initiated by the addition of
choline. ADP formation was followed spectrophotometri-
cally using a UVIKON 943 (Kontron) spectrophotometer
by measuring the decrease of NADH at 340 nm.Crystallization and data collection
Crystals of hCKApo, diffracting to 2.1 Å resolution, were
grown by the sitting-drop vapor diffusion method. Plate-
like crystals grew at 293 K to a maximum size of
20 μm×100 μm×500 μm from drops containing 1.5 μl of
11 mg/ml Δ49-hCKα2 in crystallization buffer (25 mM
Tris-HCl (pH 7.5), 25 mM KCl, 0.5 mM dithiothreitol),
0.5 μl of 0.1 M MgCl2 and 3 μl of well solution (12–20%
(w/v)PEG 3350, 0.2 M NaF). Crystals of the hCKADP and
hCKPChol complexes were obtained by soaking native
crystals for 30 min in solutions consisting of 20% PEG
3350, 0.2 M NaF, plus 10 mM ADP and 20 mM
phosphocholine, respectively. hCKADP and hCKPChol
crystals diffracted to 3.1 and 2.4 Å resolution, respectively.
All crystals belong to space group P212121, but whereas
the unit cell dimensions along the a and b axes were only
moderately changed by the soaking procedure, the c-axis
exhibited considerable lengthening: from 132.1 Å in the
apo-crystals to 158.7 Å in the ADP complex, and to 172.2 Å
in the phosphocholine complex (see Table 2). Before data
collection, crystals were washed in a cryoprotectant
solution of 30% PEG 3350, 0.2 M NaF and ligand (when
required) and then flash-cooled in a 100 K nitrogen stream.
Diffraction data on native crystals were collected at the
Cornell High Energy Synchrotron Source (CHESS) beam-
line A1, using an ADSC Quantum-210 CCD detector. Data
collections on product-bound crystals were carried out at
APS-SerCAT (Argonne National Lab) beamline ID-22,
using an Mar-300 CCD detector. All the diffraction data
were processed using XDS35 and were scaled and reduced
with programs of the CCP4 package.36 The mechanical
fragility of the crystals required extensive screenings to
identify a crystal with a suitable diffraction pattern.
However, some crystals splitting could not be avoided
and may explain the relatively high Rsym values. Data
collection statistics are summarized in Table 2.‡http://www.pymol.orgCrystallographic structure solution and refinement
The structure of hCKApo was solved by molecular
replacement in PHASER37 with search model based on
coordinates of C. elegans choline kinase A-2 (CKA-2, PDB
id 1NW1).20 The final model was refined using CNS38 and
REFMAC39 with a final R-factor of 19.8% (Rfree 25.6%).
Coordinates of the refined hCKApo were used as search
model to solve the structures of the hCKADP and hCKPChol
complexes, using the molecular replacement methods as
implemented in MOLREP.40 Top solutions from the
translation search were then subjected to rigid-body
refinement, followed by steps ofmanual rebuilding carried
out with O41 and COOT,42 and restrained refinement with
REFMAC.39 After each round of refinement, σA-weighted
2Fo–Fc and Fo–Fc difference electron density maps were
calculated and inspected. The presence of clear extraelectron density was therefore observed for ADP and
PChol, respectively. Atomic coordinates of the complexes
were refined using the same protocol employed for the
native structure, with a final R-factor of 26.3% (Rfree 32.8%)
for hCKADP, and a final R-factor of 21.4% (Rfree 25.8%) for
hCKPChol. The same set of Miller indices (5% of the total)
were set aside for free R-factor calculations during
refinement of native and ligated structures.43 Note that a
lack of traceable electron density in some regions of the
hCKADP structure prevented us from modelling ∼25% of
the residues in comparison to the apo-structure. Specifi-
cally, residues 131–139, 149–175 (missing insertion in all
pdbs), 262–268, 314–326 in chain A; 87–91, 118–121, 131–
141, 148–176, 256–277, 317–323, 388–389, 424–440 in chain
B. Refinement statistics are summarised in Table 2.
Model analysis was carried out using Procheck.44
Figures were generated with Ligplot45 and Pymol.‡
Modeling of the ADP-phosphocholine complex
Examinations of our structures, the open hCKADP and
the closed hCKPChol, suggest that the enzyme conforma-
tion observed in the latter better describes the presence of
both substrates. To position ADP in the hCKPChol
structure, we first applied a transformation matrix to the
ADP molecule, which was calculated from the change in
conformation of residues 202–210 between the hCKADP
and hCKPChol structures. These residues interact with the
adenine moiety of ADP. In addition, we optimized the
ADP position in our model by comparison with the
homologous structures of APH(3′)-IIIa and cAPK.
Protein Data Bank accession codes
Coordinates and structure factors have been deposited
in the RCSB Protein Data Bankwith accession codes 2CKO
(hCKApo), 2CKP (hCKADP), and 2CKQ (hCKPChol).Acknowledgements
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